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data consist, amongst others, of Diagnostic Related
Groups (DRG), severity of illness, risk of mortality,
number of procedures and comorbidity. Regression
analysis was used to estimate the impact of these pathol-
ogy-related parameters on the use of resources for
medical imaging. RESULTS: All pathology-related 
parameters have a statistically signiﬁcant impact on 
the consumption of medical imaging. Fifty-seven and
three–tenths percent of the case wise variation in utilisa-
tion of resources can be explained by the different para-
meters. However, the interaction of DRG with the
severity of illness in itself explains 46.7% of this varia-
tion. CONCLUSIONS: Pathology-related parameters,
especially the interaction of DRG with the severity of
illness, can be used to determine a lump sum fee that
could partly (+/-50%) replace the in essence fee for
service based payment system currently in practice.
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OBJECTIVE: This paper compares the prices of top
selling generic drugs in Canada with prices for compara-
ble generic products in the United States. METHODS:
The research examined the prices of 27 top selling (in
2001) generic prescription medicines in Canada that were
marketed in both Canada and the United States. The
sample represented approximately 36% of total generic
sales in Canada. For each of the generic medicines a 
representative presentation (strength/dosage form) was
selected—generally the top selling presentation of the
medicine. The prices were the Q1 2002 Canadian ex-
factory prices as listed in the Québec provincial govern-
ment formulary and the US Federal Supply Schedule (FSS)
prices. These prices generally represent the best available
prices in the two countries. RESULTS: Preliminary results
indicate that of the 27 leading generic drug products
examined, 21 had higher prices in Canada than in the
U.S. By all measures Canadian generic prices of the
sample drugs were higher than those in the U.S.: Mean:
+155%; Weighted Mean: +37%; Median +51%. Annual
savings in excess of C$150 million would result if 
Canadians had access to FSS prices for the sample drugs.
If the price differences seen in the sample can be extrap-
olated to all generic drugs available in Canada, the poten-
tial annual savings would exceed C$400 million.
CONCLUSIONS: It is generally accepted that the ex-
factory prices of innovator (brand name) prescription
drugs are signiﬁcantly lower in Canada than in the United
States. It was therefore surprising to ﬁnd the opposite
result for generic drugs. Several factors may contribute to
higher Canadian generic prices. The Canadian generic
industry is highly concentrated (relative to the US) with
the market dominated by two large generics ﬁrms. Sec-
ondly, provincial government reimbursement policies dis-
courage discounting and feature published formularies
that typically establish ex-factory prices for all classes of
customer.
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OBJECTIVES: Spanish Health Administration has devel-
oped some regulatory actions to check the growth of
drugs expenditure. Speciﬁcally, in 1999, Government
approved a reference price system for many drug groups
(homogeneous). Here, we present the initial data from a
study of drug consumption and a estimation of the saving
with the prescriptions of generic drugs. METHODS:
This study was divided into 2 periods: 1990–1998 and
1999–2002. In the second, the inﬂuence of the reference
price system implementation will be observed. Data from
Spanish NHS about drug consumption were provided by
the Ministry of Health and Consumer Affairs. We elabo-
rated our own database. Consumption was expressed as
PVP (price for sale direct to costumer, tax-free) by means
of PTAM (Peseta Millions) or €M (Euro Millions), and
was revised through CPI (Consumption Price Indexes,
Base 1990). Information about PVP drugs was obtained
from Ofﬁcial Drug Directory. DID (Dose for thousand
inhabitants and for day) was also calculated according to
DDD’s standard—Nordic Council Medicines ATC/DDD,
edition 1998. Saving estimation was calculated through
PVP minimum criteria of prescription, since the reference
price system had not been implemented yet. RESULTS:
According to consumption data obtained, in 1998, top
four therapeutic groups—29 active principles—explained
almost 34% of the whole expense—286116.2 PTAM or
2458.33 €M. Besides, if the criterion of PVP minimum
was applied, for the most usual format (package) per pre-
scription, the average saving would be almost 7%. In the
Spanish pharmaceutical market there are many prices for
speciﬁc active principles, being possible to identify the
biggest individual saving. CONCLUSIONS: Almost the
third part of NHS pharmaceutical budget in 1998 was
assigned at 29 active principles. The level of individual
saving was signiﬁcant in omeprazole (44%) or famotidine
(40%), among others.
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